Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Desk setup looking at stocks by LanaStock via iStock
Intel Stock and 3 Other Winners I Found Using Barchart’s High-Octane Stock Screener Barchart - Mon Jun 22, 10:30AM CDT

One feature within the Barchart Stock Screener tool that resonated with me is a pre-built filter known as the J-Pattern or J-Curve.

INTC : 140.52 (+4.87%)
RYTM : 100.14 (+3.46%)
$SPX : 7,478.26 (-0.30%)
GEV : 1,123.41 (+1.23%)
MRNA : 59.88 (-6.38%)
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 GlobeNewswire - Mon Jun 15, 3:01PM CDT

 -- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- - - Bivamelagon therapy achieved progressive reductions...

RYTM : 100.14 (+3.46%)
 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 GlobeNewswire - Sat Jun 13, 7:01AM CDT

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in...

RYTM : 100.14 (+3.46%)
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome GlobeNewswire - Fri Jun 12, 3:01PM CDT

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 100.14 (+3.46%)
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026 GlobeNewswire - Fri May 29, 7:00AM CDT

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 100.14 (+3.46%)
Buy Button by Formatoriginal via Shutterstock
3 Gold-Medal Mutual Funds to Buy Now WealthUp - Thu May 28, 5:01PM CDT

These mutual funds are the crème de la crème of their respective investment categories.

NVDA : 208.96 (-0.82%)
GOOGL : 348.31 (-5.36%)
ONC : 270.77 (+0.23%)
TDVG : 48.79 (+0.41%)
RYTM : 100.14 (+3.46%)
MU : 1,190.08 (+4.95%)
DODIX : 12.80 (+0.23%)
V : 327.42 (+0.06%)
ROST : 236.71 (+1.68%)
PRDGX : 88.18 (+0.35%)
CB : 326.68 (+1.01%)
WMT : 117.22 (+0.03%)
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics GlobeNewswire - Thu May 28, 7:00AM CDT

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 100.14 (+3.46%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences GlobeNewswire - Tue May 26, 7:00AM CDT

BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 100.14 (+3.46%)
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology GlobeNewswire - Tue May 12, 7:00AM CDT

– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France – – Phase 3 analyses...

RYTM : 100.14 (+3.46%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference GlobeNewswire - Wed May 6, 7:00AM CDT

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 100.14 (+3.46%)

Barchart Exclusives

Opendoor Is Cutting Nearly 250 Positions in India as It Builds Leaner AI-Driven Teams in America. What This Means for OPEN Stock. Barchart - 6 minutes ago
Opendoor Technologies is cutting roles as it shifts toward an AI-driven model with new leadership under CEO Kaz Nejatian. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.